State Street Corp Oyster Point Pharma, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.6 - $11.2 $549,486 - $1.71 Million	-152,635 Reduced 75.72%	48,934 $212,000
Q1 2022 May 16, 2022	BUY	$8.58 - $17.65 $328,107 - $674,953	38,241 Added 23.41%	201,569 $2.35 Million
Q4 2021 Feb 14, 2022	BUY	$10.17 - $18.96 $6,325 - $11,793	622 Added 0.38%	163,328 $2.98 Million
Q3 2021 Nov 15, 2021	BUY	$11.67 - $18.07 $263,730 - $408,363	22,599 Added 16.13%	162,706 $1.93 Million
Q2 2021 Aug 16, 2021	BUY	$16.25 - $21.51 $521,202 - $689,911	32,074 Added 29.69%	140,107 $2.41 Million
Q1 2021 May 17, 2021	SELL	$17.92 - $25.86 $52,380 - $75,588	-2,923 Reduced 2.63%	108,033 $1.98 Million
Q4 2020 Feb 16, 2021	BUY	$18.13 - $25.18 $159,979 - $222,188	8,824 Added 8.64%	110,956 $2.09 Million
Q3 2020 Nov 10, 2020	BUY	$17.83 - $29.12 $109,850 - $179,408	6,161 Added 6.42%	102,132 $2.16 Million
Q2 2020 Aug 14, 2020	BUY	$27.86 - $35.93 $42,291 - $54,541	1,518 Added 1.61%	95,971 $2.77 Million
Q1 2020 May 11, 2020	BUY	$23.65 - $40.96 $2.23 Million - $3.87 Million	94,453 New	94,453 $3.31 Million

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.